Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etoposide dosage and pharmacodynamics

S P Joel1, R Shah, M L Slevin

  • 1Department of Medical Oncology, St. Bartholomew's Hospital, West Smithfield, London, UK.

Cancer Chemotherapy and Pharmacology
|January 1, 1994
PubMed
Summary

Etoposide dosing requires adjustment in patients with impaired renal function, low albumin, or elevated liver enzymes to manage myelotoxicity. Age also influences etoposide clearance and toxicity, necessitating careful monitoring and potential dose reduction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Extremely-High-Energy Neutrinos and First Constraints on the Ultrahigh-Energy Cosmic-Ray Proton Fraction with IceCube.

Physical review letters·2025
Same author

Predicting disease-overarching therapeutic approaches for congenital disorders of glycosylation using multi-OMICS.

Molecular genetics and metabolism·2025
Same author

Predicting disease-overarching therapeutic approaches for Congenital Disorders of Glycosylation using multi-OMICS.

bioRxiv : the preprint server for biology·2025
Same author

Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma.

ESMO open·2025
Same author

Measurement of Atmospheric Neutrino Oscillation Parameters Using Convolutional Neural Networks with 9.3 Years of Data in IceCube DeepCore.

Physical review letters·2025
Same author

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Pharmacy

Background:

  • Etoposide is a key chemotherapy agent for small-cell lung cancer and lymphoma.
  • Its efficacy is schedule-dependent, but dose-response relationships for anti-tumour activity are less clear than for myelosuppression.
  • Patient variability in etoposide's effects necessitates understanding influencing factors.

Purpose of the Study:

  • To investigate factors affecting etoposide's pharmacodynamic effects, particularly hematologic toxicity.
  • To identify patient groups at risk for adverse events.
  • To correlate pharmacokinetic parameters with physiological factors and toxicity.

Main Methods:

  • Analysis of pharmacokinetic and physiological parameters in relation to etoposide toxicity.

Related Experiment Videos

  • Evaluation of renal function, serum albumin, liver enzymes, and age as predictive factors.
  • Correlation of drug clearance and area under the plasma concentration-time curve (AUC) with toxicity.

    • Main Results:

    • Impaired renal function reduces etoposide clearance, increasing exposure and myelotoxicity, recommending a 30% dose reduction.
    • Low serum albumin (< 35 g/l) increases free drug fraction and toxicity, suggesting a 30%-40% dose reduction.
    • Elevated liver enzymes and increasing age were also associated with increased toxicity and altered pharmacokinetics, indicating need for dose adjustment or monitoring.

    Conclusions:

    • Specific patient groups (renal dysfunction, hypoalbuminemia, elevated liver enzymes, elderly) require dose adjustments for etoposide to mitigate myelotoxicity.
    • Pharmacokinetic variability significantly impacts etoposide's safety profile.
    • Further research is needed to optimize individualized etoposide therapy based on pharmacokinetics for improved anti-tumour activity and reduced toxicity.